李丹 副主任医师，副教授
硕士招生类型：学术型、专业型
硕士招生专业：影像医学与核医学
博士招生类型：无
博士招生专业：无
所在院系：附属第十人民医院
联系方式：plumredlinda@163.com
课题组链接：
研究方向
主要任职
科研业绩

甲状腺癌分子机制研究，甲状腺疾病微生态学研究，核医学影像人工智能数据平台开发
Research of molecular mechanism of thyroid cancer; Microecology research in thyroid disease; Development of artificial intelligence data platform in nuclear medicine
1.上海医学会核医学分会，青年委员，2017至今
2.中国医学影像技术研究会核医学分会青年委员会，委员，2016至今
3.中华医学会核医学分会，信息传媒工作组，组员，2015至今
4.中华医学会核医学分会，对外交流学组，组员，2015至今
1.Shanghai Medical Society, Nuclear medicine branch, youth committee, 2017-present
2.China Medical Imaging Research Institute, Nuclear medicine branch, youth committee, 2016-present
3.CSNM, Chinese Society of Nuclear Medicine， member, 2015-present
作为项目负责人及参与人共承担科研项目13项，其中主持国自然及市局级科研项目共5项，前后参与国自然项目共8项。共发表文章近40篇，其中以第一作者发表SCI文章共10篇。
承担科研项目情况：1．2016年度国家自然科学基金（青年项目）：MiR-107靶向TDG调节乳头状甲状腺癌放射性碘耐受机制研究。项目编号：**。资助金额：21.6万；资助时间：2016.01-2018.12。
2.“中央高校基本科研业务费专项资金”（同济大学）：聚氨酯纳米基因载体的构建及肿瘤治疗。, 资助金额：10万；资助时间：2015.07-2017.07。
3.上海市第十人民医院攀登人才培养计划优秀青年医师（科研型）：联合aminoPVA-USPIO与MPO-Gd成像检测MS早期炎性病变的实验研究。 资助金额：8万；资助时间：2014.01-2015.12。
4.2014年度同济大学优秀人才培养行动计划：巨噬细胞成像与髓过氧化物酶成像评估4-氨基酰肼治疗多发性硬化症的效果。资助金额：10万；资助时间：2014. 01-2015.12。
5.2013年度上海市卫生和计划生育委员会青年科研项目：MiR-302靶向TRIM24调节放射性碘耐受机制研究。资助金额：2万；资助时间： 2013.10-2015.09。
6.参与国自然项目编号：**、**、**、**、**、**、**、**。
参加国际学术活动：1.The 56th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine. Oral Presentation: “The Current Therapy Status of Nuclear Medicine in China”, Nagoya, Aichi Prefecture, Japan. 2016.11.3~11.5.
2.The 1st Asian Youth Summer Camp of Nuclear Medicine. The First Price for the 1st Asian Youth Teaching Competition of Nuclear Medicine Practice in English. Shengyang, China, 2016.07.14. （获中日韩英文教学比赛一等奖）
3.Oral presentation: “The research of chemotactic factor changes in dedifferentiated thyroid cancer”. 11th Asia Oceania Congress of Nuclear Medicine and Biology in conjunction with the 54th Annual Autumn Meeting of the Korean Society of Nuclear Medicine, Jeju, Korea. 2015.10.31~11.4
4.Oral presentation: “Theranostic Nanoparticles Based on Bioreducible PEI–Coated Iron Oxide for Tumor Gene Therapy and Imaging”. Japan-China Nuclear Medicine Exchange Seminar, the 54th Annual Meeting in Osaka, Japan, 2014.11.6.
5.Dan Li，Chao Lin, Zhongwei Lv*. 2nd Sino-American Nuclear Conference, New Orleans, LA, USA. 2013.01.26-28. (获“口头汇报优秀奖”)
6.Dan Li, Zhongwei Lv*. The 1st Sino-American Conference on Nuclear Medicine, Beijing, China, 2011.02.24-28.（获“杰出表现奖”）
发表文章SCI文章：第一作者
1.Li D, Tang X, Pulli B, Lin C, Zhao P, Cheng J, Lv Z, Yuan X, Luo Q, Cai H, Ye M. Theranostic nanoparticles based on bioreducible polyethylenimine-coated iron oxide for reduction-responsive gene delivery and magnetic resonance imaging. Int J Nanomedicine. 2014, 9: 3347-61. IF=4.32
2.Li D, Cai H, Hou M, Fu D, Ma Y, Luo Q, Yuan X, Lv M, Zhang X, Cong X, Lv Z. Effects of indoleamine 2,3-dioxygenases in carbon tetrachloride-induced hepatitis model of rats. Cell Biochem Funct. 2012 Jun;30(4): 309-14. IF=2.016
3.Xia W, Li D（并列第一）, Wang G, Ni J, Zhuang J, Ha M, Wang J, Ye Y. Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy. Cancer Gene Ther. 2016, Oct, 23(10): 333-340. IF=2.532。
4.Zhu X, Li D（并列第一）, Yu F, Jia C, Xie J, Ma Y, Fan S, Cai H, Luo Q, Lv Z, Fan L. MiR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein. Oncotarget. 2016, Mar 15, 7(11): 13139-13152. IF=5.008
5.Xie J, Yu F, Li D（并列第一）, Zhu X, Zhang X, Lv Z. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2. Tumour Biol, 2016, Jan, 37(1): 1197-1204. IF=2.926
6.Yu F, Lv M, Li D（并列第一）, Cai H, Ma L, Luo Q, Yuan X, Lv Z. MiR-506 Over-Expression Inhibits Proliferation and Metastasis of Breast Cancer Cells. Med Sci Monit, 2015, Jun, 10, 21: 1687-1692. IF=1.405
7.Ye M, Li D（并列第一）, Yang J, Xie J, Yu F, Ma Y, Zhu X, Zhao J, Lv Z. MicroRNA-130a Targets MAP3K12 to Modulate Diabetic Endothelial Progenitor Cell Function. Cell Physiol Biochem. 2015, May, 36(2): 712-726. IF=4.652
8.Zhang X, Li D（并列第一）, Li M, Ye M, Ding L, Cai H, Fu D, Lv Z. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development. Int J Cancer. 2014, Jan, 15, 134(2):257-267. IF=5.531
9.Zuo K, Li D（并列第一）, Pulli B, Yu F, Cai H, Yuan X, Zhang X, Lv Z. Short-hairpin RNA-mediated Heat shock protein 90 gene silencing inhibits human breast cancer cell growth in vitro and in vivo. Biochem Biophys Res Commun. 2012, May, 4, 421(2): 396-402. IF=2.371
10.Hui Hua, Xiaoping Zhang, Dan Li（并列第一）, Jie Zou, Zhongwei Lv. Pharmacodynamics of julibroside J8 and J12 in inhibiting angiogenesis. Asian Biomedicine, 2011, Dec, 5(6): 755-763. IF=0.134
其他作者 ：1.Liu L, Yang J, Zhu X, Li D, Lv Z, Zhang X. Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. FEBS J. 2016 Apr 19. doi: 10.1111/febs.13741.
2.Pulli B, Bure L, Wojtkiewicz GR, Iwamoto Y, Ali M, Li D, Schob S, Hsieh KL, Jacobs AH, Chen JW. Multiple sclerosis: myeloperoxidase immunoradiology improves detection of acute and chronic disease in experimental model. Radiology. 2015 May;275(2):480-9.
3.Han Y, Jia C, Cong X, Yu F, Cai H, Fang S, Cai L, Yang H, Sun Y, Li D, Liu J, Xie R, Yuan X, Zhong X, Li M, Wei Q, Lv Z, Fu D, Ma Y. Increased Expression of TGFβR2 Is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients Treated with Chemotherapy. PLoS One. 2015 Aug 7;10(8):e**.
4.Zhao G, Guo J, Li D, Jia C, Yin W, Sun R, Lv Z, Cong X. MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line. DNA Cell Biol. 2013, 32(12): 699-707.
5.Yu F, Lv M, Cai H, Li D, Yuan X, Lv Z. Therapeutic effect of 188Re-MAG3-depreotide on non-small cell lung cancer in vivo and in vitro. Int J Clin Exp Pathol. 2013, 6(3): 421-430.
6.Zhang X, Mao H, Chen JY, Wen S, Li D, Ye M, Lv Z. Increased expression of microRNA-221 inhibits PAK1 in endothelial progenitor cells and impairs its function via c-Raf/MEK/ERK pathway. Biochem Biophys Res Commun. 2013, 431(3): 404-408.
7.Zhang X, Li M, Zuo K, Li D, Ye M, Ding L, Cai H, Fu D, Fan Y, Lv Z. Upregulated miR-155 in Papillary Thyroid Carcinoma Promotes Tumor Growth by Targeting APC and Activating Wnt/β-Catenin Signaling. J Clin Endocrinol Metab. 2013, 98(8): E1305-1313.
8.Fu D, Cong X, Ma Y, Cai H, Cai M, Li D, Lv M, Yuan X, Huang Y, Lv Z.Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298,468 subjects. PLoS One. 2013, 8(2): e55727.
9.Yu F, Lü ML, Zhang XP, Fu D, Hou M, Cai HD, Li D, Wang J, Yuan XY, Lü ZW, Dong F. Pre-clinical evaluation of a new indirectly labeled 99mTc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-depreotide with HYNIC as bifunctional chelator. Chin Med J (Engl). 2012, 125(14): 2538-2542.
10.Lv M, Xiaoping X, Cai H, Li D, Wang J, Fu X, Yu F, Sun M, Lv Z. Cytokines as prognstic tool in breast carcinoma. Front Biosci. 2011, 16: 2515-2526.
11.Zuo KQ, Zhang XP, Zou J, Li D, Lv ZW. Establishment of a paclitaxel resistant human breast cancer cell strain (MCF-7/Taxol) and intracellular paclitaxel binding protein analysis. J Int Med Res. 2010, 38(4): 1428-1435.
中文文章：通讯作者：1.张博佳，韦松华，陈炜，李丹。抑制NSCLC细胞株H1299中EIF5A2表达对肿瘤生长及转移的影响。同济大学学报（医学版），2017, 38(3): 30-34.
第一作者：1.李丹，张菁，白鑫，黄飚，张艺，吕中伟，屠红。新型肝癌标志物Glypican-3时间分辨免疫荧光法的建立。中华核医学杂志，2011,31（3）：201-204.
2.李丹，侯敏，吕中伟，吕明丽，蔡海东，余飞，孙明。（125）碘标记三链形成寡核苷酸对肝癌细胞中病毒复制和细胞生长的抑制作用。上海医学，2010,33（3）：290-294.
3.李丹，吕中伟。反基因技术用于肿瘤治疗的研究进展。同济大学学报（医学版），2008,29:84-90.
4.李丹，吕中伟。核医学显像在肿瘤诊断中的应用进展。中华医学与健康，2006,7:42-44.
5.李丹，黄飚，吕中伟。新型肝癌标志物Glypican-3时间分辨免疫荧光法的建立。中华医学会第九次全国核医学学术会议。2011-08-24.
6.李丹，林超，吕中伟。多模态磁性-荧光可降解纳米探针的研制及成像研究。中华医学会第九次全国核医学学术会议。2011-08-24.
其他作者：1.吕明丽，余飞，陆思琦，李丹，王舰，吕中伟。肥胖青年骨密度状况分析。同济大学学报（医学版），2012,33（4）：90-93.
2. 余飞，吕明丽，蔡海东，李丹，吕中伟。基于双功能螯合剂的99mTc间接标记depreotide的探索。同济大学学报（医学版）,2012,33(3):10-16.
3. 付兴建，王舰，吕明丽，李丹，吕中伟。基于MFC编程的图像处理在核医学中的应用。微计算机信息，2012, 4: 157-159.
4. 王舰，蔡海东，吕明丽，付兴建，李丹，吕中伟。131I固定计量法及计算计量法治疗甲亢的疗效评价。同济大学学报（医学版），2012，33（1）:83-87.
5. 余飞，吕明丽，蔡海东，李丹，袁雪宇，吕中伟。 血浆ANF与99mTc-DTPA肾动态显像的联合监测在糖尿病肾病中的意义。放射免疫学杂志。2013，26（01）：22-24.
6. 吕明丽，余飞，陆思琦，王舰，李丹，吕中伟。肥胖青年骨密度状况分析。第五次全国青年核医学学术会议，2012-05-11.
7. 余飞，吕明丽，蔡海东，李丹，袁雪宇，吕中伟。miR-506在乳腺肿瘤细胞增殖及转移中的作用。同济大学学报（医学版）2013，1:25-29.
8. 余飞，吕明丽，蔡海东，李丹，袁雪宇，吕中伟。
RESEARCH REPORT：1.**，NSFC (Natural Science Foundation of China), 2016/01~2018/12
2.Basic Reasearch Specific Fund of Central Colleges and Universities，Tongji University，2015/07~2017/07
3.Training plan of Excellent talent, Shanghai 10th People’s Hospital, 2014/01~2015/12
4.2014 Training plan of Excellent talent, Tongji University, 2014/01~2015/12
5.Youth Scientific Research Project in 2013, Shanghai Health Bureau, 2013/10~2015/09
6.Participate in NSFC projects: **, **, **, **, **, **, **, **.
INTERNATIONAL ACADEMIC EXCHANGES :1.The 56th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine. Oral Presentation: “The Current Therapy Status of Nuclear Medicine in China”, Nagoya, Aichi Prefecture, Japan. 2016.11.3~11.5.
2.The 1st Asian Youth Summer Camp of Nuclear Medicine. The First Price for the 1st Asian Youth Teaching Competition of Nuclear Medicine Practice in English. Shengyang, China, 2016.07.14.
3.Oral presentation: “The research of chemotactic factor changes in dedifferentiated thyroid cancer”. 11th Asia Oceania Congress of Nuclear Medicine and Biology in conjunction with the 54th Annual Autumn Meeting of the Korean Society of Nuclear Medicine, Jeju, Korea. 2015.10.31~11.4
4.Oral presentation: “Theranostic Nanoparticles Based on Bioreducible PEI–Coated Iron Oxide for Tumor Gene Therapy and Imaging”. Japan-China Nuclear Medicine Exchange Seminar, the 54th Annual Meeting in Osaka, Japan, 2014.11.6.
5.Excellent Oral Presentation. 2nd Sino-American Nuclear Conference, New Orleans, LA, USA. 2013.01.26-28.
6.Outstanding Performance. The 1st Sino-American Conference on Nuclear Medicine, Beijing, China, 2011.02.24-28.